Investing.com -- UBS Global Research has initiated coverage on Zealand Pharma A/S (CSE:ZELA) a clinical-stage European biotech focused on obesity, with a “buy” rating and a price target of DKK760, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback